Sign in Subscribe
Institutional investments

SELLAS Life Sciences Group Exercises Warrants for $31 Million in Gross Cash Proceeds

Strategic Insights

— 1 min read

SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, has announced the immediate exercise of warrants to purchase up to 22,363,714 shares of its common stock. This move is expected to bring in approximately $31.0 million in gross cash proceeds. The company has also announced the issuance of new registered warrants to purchase up to 22,363,714 shares of its common stock at an exercise price of $2.00. A.G.P./Alliance Global Partners and Maxim Group LLC acted as financial advisors in connection with the transaction.

Key Takeaways:

  • SELLAS Life Sciences Group has exercised warrants to purchase up to 22,363,714 shares of its common stock, generating approximately $31.0 million in gross cash proceeds.
  • The company has issued new registered warrants to purchase up to 22,363,714 shares of its common stock at an exercise price of $2.00, exercisable immediately and expiring five years from the date of issuance.
  • A.G.P./Alliance Global Partners and Maxim Group LLC acted as financial advisors in connection with the transaction.
  • The shares of common stock issuable upon exercise of the Existing Warrants have been registered pursuant to effective registration statements on Form S-3.
  • The offering is being made pursuant to an effective shelf registration statement on Form S-3 previously filed with the SEC.
  • A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website.

Statistics:

  • 22,363,714 shares of common stock will be purchased through the exercise of the Existing Warrants.
  • The gross cash proceeds from the exercise of the Existing Warrants are approximately $31.0 million.
  • The exercise price of the new registered warrants is $2.00.
  • The new registered warrants will expire five years from the date of issuance.

Sources:

  • GlobeNewswire, "SELLAS Life Sciences Group Exercises Warrants for $31 Million in Gross Cash Proceeds" (October 27, 2025)
  • SELLAS Life Sciences Group, " NOTICE OF EXERCISE OF WARRANTS TO PURCHASE COMMON STOCK" (Form S-3, File No. 333-278337 and File No. 333-278334)
  • US Securities and Exchange Commission, "SELLAS LIFE SCIENCES GROUP, INC. (CT?SLS)"

Read more